DOCSLIB.ORG

Development of an in Vitro Diagnostic Technique for Malassezia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of an in Vitro Diagnostic Technique for Malassezia Development of an In Vitro Diagnostic Technique for Malassezia furfur A thesis submitted in partial fulfilment of the requirement for the Degree of Master of Science in Microbiology in the University of Canterbury by Stephanie Fiona ~uick University of Canterbury vw+ of Contents 1 ! :) TABLE OF CONTENTS Ta hie of Contents ............................................................ 8 •••••••• 0 ••• "." ••••••••••• 1 List of Tables ............................. o ••••••• o ••••••••••••••••••••••••••••• 0 •••••••••• 0 •••••••••••••• 7 List of Figures ........................................................................................... 8 Abstract............................. o ••••• 0 ••• 0' ••••••••••••••••••••••••••••••••••••••••••••••••••••• 00 •••••• 9 Acknowledgemen ts ..... o ••••• e •••••••••••• e •••••••••••••••••••••••••••••••••••••••• o ••••• o ••••••• e •• l 0 1. INTRODUCTION .o, •• o •••••••• e •••• O' •••• O •••••••••••••••••••••••••••••••••••••••••••••••••••••• 11 1.1 THE GENUS MALASSEZIA ..................................................................... 11 1.2 TAXONOMY OF MALASSEZIA FURFUR .................................................. 12 1.3 MORPHOLOGy .................................................................................... 15 1.4 PATHOGENICITY ................................................................................. 18 1.5 fIABITAT ............................................................................................ 20 1.6 GROWTH OF MALASSEZIA FURFUR IN VITRO ......................................... 22 1.7 IDENTIFICATION ................................................................................. 24 1.8 CONTROL ........................................................................................... 25 1.9 ANTIMICROBIAL COMPOUNDS PRODUCED BY MALASSEZIA FURFUR ... 26 2. MATERIALS AND METHODS ..................................... e ••••••••••••••••• 27 2.1 CULTURE ............................................................................................ 27 Table of Contents 2 2.1.1 Culturing o/Freeze-Dried Isolate ............................................................... 27 2.1.2 Culturing o/Skin Isolate ............................................................................. 28 2.2 IDENTIFICATION METHODS FOR MALASSEZIA FURFUR ......................... 29 2.3 GROWTH MEDIA ................................................................................ 30 2.3.1 Media Incorporating Indicators .................................................................. 31 2.3.1.1 Utilisation of Urea ............. 88 ••• "& •••••• 08 •••••• 08 •••• '11 ••••••••••••••••••••••• 111 •••••••••••••••••• 31 2.3.1.2 Utilisation of Nitrogen Sources ............................................................ 31 2.3.1.3 Utilisation of Amides ............................................................................ 032 2.3.2 Media Incorporating Lipids ........................................................................ 32 2.3.2.1 Utilisation of Some PoJyoxyethylene Sorbitan Esters (Tween ~ ...... 32 2.3.2.2 Utilisation of Cholesterol, Egg Yolk and Milk .................................. 33 2.3.3 Media Incorporating Other Nutrients ......................................................... 33 2.3.3.1 Growth on Sweat Medium.................................................................... 33 2.3.3.2 Utilisation of Taurocholic Acid ............................................................ 34 2.3.3.3 Assessment of Substrate Assimilation System ....................... 34 2.3.31104 Gelatine Hydrolysis .... o •••••••••••• ooov •• "' .............................. iI .. " ......................... O"" ••• 34 2.4 INDUCTION OF THE HYPHAL PHASE OF MALASSEZIA FURFUR .............. 35 2.5 RESPONSE TO INHIBITORY AGENTS .................................................... 36 2.5.1 Antifungal Agents ........................................................................................ 36 2.5.1.1 Amphotericin B Sensitivity .. 0 •••• 0 •••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 36 2.5.1.2 Nystatin Sensitivity ................ 0 ••••••••••••••••••• 0 •••••••••••••••••••••••••••••••••••••••••• 37 2.5.1.3 Thiarubrine A Sensitivity ........................................................................... 37 2.5.1.4 Agricultural Fungicide Sensitivity ....................................................... 38 2.5.2 Effect o/Fungal Cell Wall Degrading Enzymes ......................................... 39 Table of Contents 3 2.6 ANTIMICROBIAL AGENTS PRODUCED BY MALASSEZIA FURFUR ........... 41 2.6.1 Azelaic Acid Assay ...................................................................................... 41 2.6.2 Ethyl Acetate Extraction ofFungal Metabolites from Malasseziafurfur ... 43 3. RESULTS ................................................... 0 •••••••••••••••••••••••••••••••••••••••• 45 3.1 CULTURE ............................................................................................ 45 3.1.1 Culturing ofFreeze-Dried Isolate ............................................................... 45 3.1.2 Culturing ofSkin Isolate ............................................................................. 45 3.2 IDENTIFICATION METHODS FOR MALASSEZIA FURFUR ......................... 45 3.3 GROWTH MEDIA ................................................................................ 46 3.3.1 Media Incorporating Indicators .................................................................. 46 3.3.1.1 Utilisation of Urea ................................................................................. 46 3.3.1.2 Utilisation of Nitrogen Sources ............................................................ 49 3.3.1.3 Utilisation of Amides ............................................................................. 49 3.3.2 Media Incorporating Lipids ........................................................................ 52 3.3.2.1 Utilisation of Polyoxyethylene Sorbitan Esters (Tween®) .................. 52 3.3.2.2 Utilisation of Cholesterol, Milk and Egg Yolk ................................... 53 3.3.3 Media Incorporating Other Nutrients ......................................................... 54 3.3.3.1 Growth on Sweat Medium .................................................................... 54 3.3.3.2 Utilisation of Taurocholic Acid ............................................................ 54 3.3.3.3 Assessment of ID 32C Substrate Assimilation System ....................... 57 3.3.3.4 Gelatine Hydrolysis ............................................................................... 58 3.4 INDUCTION OF THE HYPHAL PHASE OF MALASSEZIA FURFUR .............. 59 3.5 REACTION TO INHIBITORY AGENTS .................................................... 60 Table of Contents 4 3.5.1 Antifungal Agents ........................................................................................ 60 3.5.1.1 Amphotericin B Sensitivity ."" ............................................................... 60 3.5.1.2 Nystatin Sensitivity .............. ,.................................................................. 61 3.5.1.3 Thiarubrine A Sensitivity .............................................. "....... 0 •••••• " ••••••• 64 3.5.1.4 Agricultural Fungicide Sensitivity ....................... u .............................. 67 3.5.2 Effect ofFungal Cell Wall Degrading Enzymes ......................................... 69 3.6 ANTIMICROBIAL AGENTS PRODUCED BY MALASSEZIA FURFUR ............ 72 3.6.1 Azelaic Acid Assay ...................................................................................... 72 3.6.2 Ethyl Acetate Extraction ofFungal Metabolites ofMalasseziafurfur ....... 72 4. DISCUSSION ............••..••...••.•.•..•.....•..••.••••..•....•......•......•... ,,0 •••••••••••••• 73 4.1 CULTlTRE AND GROWTH ..................................................................... 73 4.2 NUTRIENT REQUIREMENTS ................................................................. 74 4.3 IDENTIFICATION AND CONTROL ......................................................... 76 4.4 FlTTUREREsEARCH ............................................................................ 79 4.5 SUMMARy ...................................................................................... 80 5. REFEREN CES ...........•....•...............•..•........•...•.................... 1) ••••••••••••• 81 6. APPENDIX OF MEDIA ............... D •••••••••••••••••••••••••••••••••••••••••••••••••••• 92 6.1 DIXON'S AGAR ................................................................................... 92 6.2 DIXON'S BROlli ................................................................................. 92 6.3 DIXON'S AGAR WIlli CYCLOHEXIMIDE, CHLORAMPHENICOL AND GENTAMICIN (CCG) ................................................................................. 93 Table of Contents 5 6.4 SABOURAUD DEXTROSE AGAR (SDA) ............................................... 94 6.5 SDA WITH OLIVE OIL ......................................................................... 94 6.6 SDA WITH TWEEN SO® AND GLyCEROL ............................................. 95 6.7 SDA WITH TWEEN SO®, GLYCEROL AND CCG .................................. 95 6.S CHRISTENSEN'S UREA AGAR ............................................................. 96 6.9 CHRISTENSEN'S UREA AGAR WITH TWEEN SO® AND GLYCEROL ....... 97 6.10 UREA AGAR BASE .......................................................................... 97 6.11 PHENOL RED BROTH BASE ............................................................
Load more

Recommended publications
  • Comparison of Efficacy of Combination of 2% Ketoconazole
    Open Access Original Article Comparison of Topical Treatments in Pityriasis Versicolor Pak Armed Forces Med J 2018; 68 (6): 1725-30 COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR Ayesha Anwar, Naeem Raza, Najia Ahmed, Hyder Ali Awan* Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *King Abdul Aziz Naval Base, Jubail, Saudia Arabia ABSTRACT Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor. Study Design: Randomized controlled trial. Place and Duration of Study: Dermatology department, Pak Emirates Military Hospital Rawalpindi, from Oct 2016 to Apr 2017. Material and Methods: Sixty patients of Pityriasis versicolor, both male and female were included in study. Diagnosis of Pityriasis versicolor was made clinically and confirmed microscopically by examining skin scrapings for fungal hyphae. Patients with concomitant systemic illnesses or those who had received anti-fungal in last three months were excluded from study. Random number tables were used to allocate patients to the two treatment groups. Group A received 2% ketoconazole shampoo twice per week for four weeks plus topical 1% clotrimazole twice daily application for 2 weeks. Group B received only topical therapy with 1% clotrimazole cream applied twice daily for 2 weeks. Assessment of treatment efficacy was done by clinical examination of patient and microscopy of skin scrapping for fungal hyphaedone at baseline and at end of study (4 weeks of treatment). A negative clinical examination and negative skin scrapping for fungal hyphae was considered effective therapeutic response.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Mycology Proficiency Testing Program
    Mycology Proficiency Testing Program Test Event Critique January 2013 Mycology Laboratory Table of Contents Mycology Laboratory 2 Mycology Proficiency Testing Program 3 Test Specimens & Grading Policy 5 Test Analyte Master Lists 7 Performance Summary 11 Commercial Device Usage Statistics 15 Mold Descriptions 16 M-1 Exserohilum species 16 M-2 Phialophora species 20 M-3 Chrysosporium species 25 M-4 Fusarium species 30 M-5 Rhizopus species 34 Yeast Descriptions 38 Y-1 Rhodotorula mucilaginosa 38 Y-2 Trichosporon asahii 41 Y-3 Candida glabrata 44 Y-4 Candida albicans 47 Y-5 Geotrichum candidum 50 Direct Detection - Cryptococcal Antigen 53 Antifungal Susceptibility Testing - Yeast 55 Antifungal Susceptibility Testing - Mold (Educational) 60 1 Mycology Laboratory Mycology Laboratory at the Wadsworth Center, New York State Department of Health (NYSDOH) is a reference diagnostic laboratory for the fungal diseases. The laboratory services include testing for the dimorphic pathogenic fungi, unusual molds and yeasts pathogens, antifungal susceptibility testing including tests with research protocols, molecular tests including rapid identification and strain typing, outbreak and pseudo-outbreak investigations, laboratory contamination and accident investigations and related environmental surveys. The Fungal Culture Collection of the Mycology Laboratory is an important resource for high quality cultures used in the proficiency-testing program and for the in-house development and standardization of new diagnostic tests. Mycology Proficiency Testing Program provides technical expertise to NYSDOH Clinical Laboratory Evaluation Program (CLEP). The program is responsible for conducting the Clinical Laboratory Improvement Amendments (CLIA)-compliant Proficiency Testing (Mycology) for clinical laboratories in New York State. All analytes for these test events are prepared and standardized internally.
    [Show full text]
  • In Vitro Activity of Phytosphingosines Against Malassezia Furfur and Candida Albicans*
    Acta Derm Venereol 2002; 82: 170–173 INVESTIGATIVE REPORT In vitro Activity of Phytosphingosines against Malassezia furfur and Candida albicans* PIETRO NENOFF and UWE-FRITHJOF HAUSTEIN Department of Dermatology, University of Leipzig, Leipzig, Germany Long-chain sphingoid bases, e.g. phytosphingosine , sphin- metabolic changes: the phospholipids are degradaded gosine and sphinganine, main constituents of the stratum into glycerol and free fatty acids, and glucosylsphingo- corneum, can strongly inhibit the growth of microorgan- lipids into ceramides (2). isms that are known to have undesirable eVects on the Long chain sphingoid bases, e.g. phytosphingosines skin. The aim of this study was to investigate the in vitro (PS), sphingosines, and sphinganines are known to be activity of diVerent phytosphingosine preparations against present in the stratum corneum in free form but also as Malassezia furfur, and, in comparison, against the components of ceramides. These molecules are potent common facultative pathogenic yeast Candida albicans. inhibitors of protein kinase C and as a consequence An agar dilution test for minimum inhibitory concentration they seem to be involved in the diVerentiation of epi- (MIC ) investigation of phytosphingosin e base, phyto- dermal keratinocytes. There are also reports suggesting sphingosine lactic acid salt, phytosphingosine HCl, and that sphingoid bases play an important role in regulating phytosphingosin e glycolic acid salt was carried out using the micro- ora of the skin. D.S.T. agar containing 2% olive oil and 0.2% Tween 80, It was shown that PS, the most abundant free sphin- to allow growth of the lipophilic yeast. M. furfur growth goid base in the stratum corneum, could strongly inhibit inhibition in vitro could be achieved only at extremely the growth of microorganisms which are known to have high phytosphingosin e concentrations.
    [Show full text]
  • Caenorhabditis Elegans Assay
    Identification of Antifungal Compounds Active against Candida albicans Using an Improved High-Throughput Caenorhabditis elegans Assay Ikechukwu Okoli1, Jeffrey J. Coleman1, Emmanouil Tempakakis1, W. Frank An2, Edward Holson2, Florence Wagner2, Annie L. Conery3, Jonah Larkins-Ford3, Gang Wu3, Andy Stern2, Frederick M. Ausubel3, Eleftherios Mylonakis1* 1 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America, 3 Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America Abstract Candida albicans, the most common human pathogenic fungus, can establish a persistent lethal infection in the intestine of the microscopic nematode Caenorhabditis elegans. The C. elegans–C. albicans infection model was previously adapted to screen for antifungal compounds. Modifications to this screen have been made to facilitate a high-throughput assay including co-inoculation of nematodes with C. albicans and instrumentation allowing precise dispensing of worms into assay wells, eliminating two labor-intensive steps. This high-throughput method was utilized to screen a library of 3,228 compounds represented by 1,948 bioactive compounds and 1,280 small molecules derived via diversity-oriented synthesis. Nineteen compounds were identified that conferred an increase in C. elegans survival, including most known antifungal compounds within the chemical library. In addition to seven clinically used antifungal compounds, twelve compounds were identified which are not primarily used as antifungal agents, including three immunosuppressive drugs. This assay also allowed the assessment of the relative minimal inhibitory concentration, the effective concentration in vivo, and the toxicity of the compound in a single assay.
    [Show full text]
  • Design and in Vitro Characterization of Flutrimazole Microspheres Loaded Topical Emulgel
    Online - 2455-3891 Vol 12, Issue 9, 2019 Print - 0974-2441 Research Article DESIGN AND IN VITRO CHARACTERIZATION OF FLUTRIMAZOLE MICROSPHERES LOADED TOPICAL EMULGEL MUTHADI RADHIKA REDDY1*, SOUMYASTUTIPATNAIK2 Department of School of Pharmacy, Guru Nanak Institutions Technical Campus, Hyderabad, Telangana, India. Email: [email protected] Received: 28 May 2019, Revised and Accepted: 26 July 2019 ABSTRACT Objective: Flutrimazole is a topical antifungal agent which displays potent broad spectrum in vitro activity against dermatophytes, filamentous fungi, and yeasts. The purpose of the present study is to formulate and evaluate microspheres loaded topical gel containing flutrimazole as model drug microspheres were prepared using aqueous ionotropic gelation method. Methods: Different polymers, the different drug to polymer(s) ratio(s) and other parameters were screened to study their effects on the properties of microspheres and to optimize each parameter. The controlled release emulgel was formulated by changing the polymer ratio. Fourier transform infrared study confirmed the purity of the drug, concede no interaction between the drug and excipients and analyze the parameters affecting the morphology and other characteristics of the resultant products employing scanning electron microscopy. Results: Microspheres loaded topical gel has been shown that encapsulation and controlled release of flutrimazole could reduce the side effect while also reducing percutaneous absorption when administered to the skin. The microspheres obtained
    [Show full text]
  • Topical Antifungals Used for Treatment of Seborrheic Dermatitis
    Journal of Bacteriology & Mycology: Open Access Review Article Open Access Topical antifungals used for treatment of seborrheic dermatitis Abstract Volume 4 Issue 1 - 2017 Seborrheic dermatitis is a common inflammatory condition mainly affecting scalp, Sundeep Chowdhry, Shikha Gupta, Paschal face and other seborrheic sites, characterized by a chronic relapsing course. The mainstay of treatment includes topical therapy comprising antifungals (ketoconazole, D’souza Department of Dermatology, ESI PGIMSR, India ciclopirox olamine) and anti-inflammatory agents along with providing symptomatic relief from itching. Oral antifungals and retinoids are indicated only in the severe, Correspondence: Sundeep Chowdhry, Senior Specialist and recalcitrant cases. The objective of this review is to discuss various topical antifungals Assistant Professor, Department of Dermatology, ESI PGIMSR, available for use in seborrheic dermatitis of scalp, face and flexural areas, discuss their Basaidarapur, New Delhi, India, Tel 919910084482, efficacy and safety profiles from relevant studies available in the literature along with Email [email protected] upcoming novel delivery methods to enhance the efficacy of these drugs. Received: October 28, 2016 | Published: January 06, 2017 Keywords: seborrheic dermatitis, antifungal agents, ketoconazole, ciclopirox Introduction Discussion Seborrheic dermatitis (SD) is a common, chronic inflammatory Treatment considerations disease that affects around 1-3% of the general population in many countries including the U.S., 3-5% of patients consisting of young Treatment for SD should aim for not just achieving remission of adults. The incidence of the disease has two peaks: one in newborn lesions but also to eliminate itching and burning sensation and prevent 6 infants up to three months of age, and the other in adults of around recurrence of the disease.
    [Show full text]